ArticleFrontiers in oncology2025
Multi-parametric MRI-based radiomics nomogram for predicting lymphovascular space invasion in early-stage cervical adenocarcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop a magnetic resonance imaging (MRI)-based radiomics nomogram to predict lymphovascular space invasion (LVSI) status in patients with early-stage cervical adenocarcinoma (CAC). Methods: Clinicopathological and MRI data from 310 patients with histopathologically confirmed early-stage CAC were retrospectively analyzed. Patients were divided into training (n = 186) and validation (n = 124) cohorts. Tumor volumes of interest (VOIs) were segmented on T2-weighted imaging (FS-T2WI) and aligned to diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) maps, and T1-weighted imaging (CE-T1WI) sequences. Radiomics features were extracted and screened using Pearson correlation and least absolute shrinkage and selection operator (LASSO) regression, and a radscore was calculated for each patient. Multivariate logistic regression identified clinical risk factors, and a radiomics nomogram was constructed by integrating the radscore with clinical risk factors. Receiver operating characteristic (ROC) curves and areas under the curve (AUCs) were used to evaluate the performance of the clinical model, radiomics model, and nomogram. Decision curve analysis was used to assesses the clinical utility of the nomogram. Results: Seventeen radiomics features were selected to construct the radscore. Menopause and tumor diameter were identified as independent clinical risk factors for LVSI. The radiomics nomogram achieved AUCs of 0.80 (95% CI: 0.74-0.86) and 0.78 (95% CI: 0.69-0.86) in the training and validation cohorts, outperforming the clinical model (AUCs: 0.69 and 0.62) and comparable to the radiomics model (AUCs: 0.79 and 0.78). Decision curve analysis showed the nomogram provided clinical benefit. Conclusions: The radiomics nomogram, integrating radiomic features and clinical risk factors, could be used to predict LVSI status in early-stage CAC accurately, supporting preoperative clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.